Novel drug development is rapidly transforming the Retinitis Pigmentosa Treatment Market, with major pharmaceutical companies and biotech innovators exploring new molecules targeting retinal preservation. Many of these drugs aim to slow photoreceptor apoptosis or enhance mitochondrial function. Early-stage results show promise in protecting existing retinal cells from further degeneration....

Retinitis pigmentosa gene therapy — the viral vector-mediated delivery of functional copies of mutated genes responsible for inherited photoreceptor degeneration — represents the most transformative development in retinitis pigmentosa treatment, with the Retinitis Pigmentosa Treatment Market reflecting gene therapy as the market-defining treatment innovation. Luxturna (voretigene...

Cell-based therapies, primarily using stem cells, represent a second powerful, mutation-agnostic treatment avenue for Retinitis Pigmentosa that holds the potential for both slowing degeneration and facilitating functional replacement. Researchers are investigating multiple types of stem cells, including induced pluripotent stem cells (iPSCs), embryonic stem cells, and adult stem cells (such as...